phase III randomized Intergroup … (2024)

phase III randomized Intergroup … (1) https://doi.org/10.1200/jco.1998.16.4.1310 · phase III randomized Intergroup … (2) Full text

Journal: Journal of Clinical Oncology, 1998, №4, p.1310-1317

Publisher: American Society of Clinical Oncology (ASCO)

Authors:

  1. M Al-Sarraf
  2. M LeBlanc
  3. P G Giri
  4. K K Fu
  5. J Cooper
  6. T Vuong
  7. A A Forastiere
  8. G Adams
  9. W A Sakr
  10. D E Schuller
  11. J F Ensley

Abstract

<jats:sec>PURPOSE The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers. </jats:sec><jats:sec>MATERIALS AND METHODS Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology. </jats:sec><jats:sec>RESULTS Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P &lt; .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P &lt; .001). </jats:sec><jats:sec>CONCLUSION We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival. </jats:sec>

Publications that cite this publication

Adjuvant High-Dose Rate Brachytherapy After Chemoradiation for Treatment of Early T-Stage Nasopharyngeal Carcinoma

Jiade J. Lu, Thomas Shakespeare, Boon Cher Goh, Chua Eu Tiong, Michael Back, Rahul Mukherjee, Christopher J. Wynne, Kim Siang Luke Tan

phase III randomized Intergroup … (3) https://doi.org/10.1097/01.coc.0000046592.90778.fc

2004, American Journal of Clinical Oncology, №2, p.132-135

Scopus

WoS

Crossref citations:2

Tension Pneumocephalus Related to Radiotherapy for Nasopharyngeal Carcinoma

Esther Jimenez-Jimenez, Sebastià Sabater Martí, M. Victoria Villas

phase III randomized Intergroup … (4) https://doi.org/10.1155/2014/327380 · phase III randomized Intergroup … (5) Full text

2014, Case Reports in Oncological Medicine, p.1-4

Scopus

WoS

Crossref citations:1

Hyperfractionated Radiotherapy and Concomitant Cisplatin for Locally Advanced Laryngeal and Hypopharyngeal Carcinomas

Fernando Arias de la Vega, R. Vera García, Domínguez Domínguez, E. Villafranca Iturre, E. Martínez López, S. Miquelez Alonso, P. Romero, J. Medina Sola

phase III randomized Intergroup … (6) https://doi.org/10.1097/01.coc.0000037741.09729.f4

2003, American Journal of Clinical Oncology, №6, p.550-557

Scopus

WoS

Crossref citations:6

Chemotherapy for nasopharyngeal carcinoma

MAC-NPC (Meta-Analysis of Chemother

phase III randomized Intergroup … (7) https://doi.org/10.1002/14651858.cd004329

2003, Cochrane Database of Systematic Reviews

Crossref citations:0

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma

Shufang Liao, Bin Zhang, Yixin Su, Yufei Pan, Jian Zhang, Zhenkai Ye, Rongjun Zhang, Xiangyun Kong, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Jian Liu, Chunqiao Gan, Jinxuan Dai, Ruyun Zhang, Guanhong Luo, Xiaofei Liao, Wei Jiang

phase III randomized Intergroup … (8) https://doi.org/10.1007/s00066-024-02201-1 · phase III randomized Intergroup … (9)

2024, Strahlentherapie und Onkologie, №10, p.867-875

Scopus

WoS

Crossref citations:0

Early Nodal Response as a Predictor for Necessity of Functional Neck Dissection After Chemoradiation

Roy Vongtama, Michelle Lee, Brian Kim, Joel Sercarz, Kevin Lin, Marc A. Suchard, Steve E. Lee, Guy Juillard

phase III randomized Intergroup … (10) https://doi.org/10.1097/00130404-200411000-00002 · phase III randomized Intergroup … (11) Full text

2004, The Cancer Journal, №6, p.339-342

Scopus

WoS

Crossref citations:7

Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma

Huiyun Yang, Rongjun Zhang, Ruyun Zhang, Bin Zhang, Yuan Xie, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Wei Jiang

phase III randomized Intergroup … (12) https://doi.org/10.1007/s00066-022-01926-1 · phase III randomized Intergroup … (13)

2022, Strahlentherapie und Onkologie, №9, p.828-837

Scopus

WoS

Crossref citations:1

Gemcitabine for patients with relapsed nasopharyngeal carcinoma

L. Mileshkin, D. Rischin

phase III randomized Intergroup … (14) https://doi.org/10.1046/j.1445-5994.2002.00207.x

2002, Internal Medicine Journal, №5-6, p.275-276

Scopus

WoS

Crossref citations:0

Neurosurgical interventions for patients with nasopharyngeal carcinoma: a single institution experience

Ke Sai, Yong-gao Mou, Jing Zeng, Yan-chun Lv, Shao-yan Xi, Su Guan, Xiang-heng Zhang, Jian Wang, Chao Ke, Jian-gui Guo, Yin-sheng Chen, Zhong-ping Chen

phase III randomized Intergroup … (15) https://doi.org/10.1186/1477-7819-11-227 · phase III randomized Intergroup … (16) Full text

2013, World Journal of Surgical Oncology, №1

Scopus

WoS

Crossref citations:2

Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma

Cheng Lin, Keyu Lin, Bin Zhang, Ying Su, Qiaojuan Guo, Tianzhu Lu, Yuanji Xu, Shaojun Lin, Jingfeng Zong, Jianji Pan

phase III randomized Intergroup … (17) https://doi.org/10.1093/oncolo/oyac024 · phase III randomized Intergroup … (18)

2022, The Oncologist, №4, p.e340-e349

Scopus

WoS

Crossref citations:8

Find all citations of the publication

phase III randomized Intergroup … (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Lidia Grady

Last Updated:

Views: 6686

Rating: 4.4 / 5 (65 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Lidia Grady

Birthday: 1992-01-22

Address: Suite 493 356 Dale Fall, New Wanda, RI 52485

Phone: +29914464387516

Job: Customer Engineer

Hobby: Cryptography, Writing, Dowsing, Stand-up comedy, Calligraphy, Web surfing, Ghost hunting

Introduction: My name is Lidia Grady, I am a thankful, fine, glamorous, lucky, lively, pleasant, shiny person who loves writing and wants to share my knowledge and understanding with you.